

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2024-10-28** | Period of Report: **2024-10-25**

SEC Accession No. [0001193125-24-244725](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

Bellevue Life Sciences Acquisition Corp.

CIK: [1840425](#) | IRS No.: **845052822** | State of Incorporation: **DE** | Fiscal Year End: **1231**

Type: **8-K** | Act: **34** | File No.: [001-41390](#) | Film No.: **241398503**

SIC: **3841** Surgical & medical instruments & apparatus

Mailing Address

10900 NE 4TH STREET,
SUITE 2300
BELLEVUE WA 98004

Business Address

10900 NE 4TH STREET,
SUITE 2300
BELLEVUE WA 98004
425-635-7700

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 25, 2024

BELLEVUE LIFE SCIENCES ACQUISITION CORP.
(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-41390
(Commission
File Number)

84-5052822
(IRS Employer
Identification No.)

10900 NE 4th Street, Suite 2300, Bellevue, WA
(Address of Principal Executive Offices)

98004
(Zip Code)

Registrant's telephone number, including area code (425) 635-7700

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units, each consisting of one share of common stock, one redeemable warrant and one right	BLACU	The Nasdaq Stock Market LLC
Common stock, par value \$0.0001 per share	BLAC	The Nasdaq Stock Market LLC
Redeemable warrants, exercisable for shares of common stock at an exercise price of \$11.50 per share	BLACW	The Nasdaq Stock Market LLC
Right to receive one-tenth (1/10) of one share of common stock	BLACR	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01. Entry into a Material Definitive Agreement.

On October 25, 2024, Bellevue Life Sciences Acquisition Corp. (the “Company”) advanced a loan to OSR Holdings Co., Ltd. (“OSR Holdings”) in the amount of \$300,000 evidenced by a promissory note (the “OSR Holdings Promissory Note”) that bears interest at a rate of 3.96% per annum, compound semi-annually, and is due on October 25, 2025 (the “Maturity Date”). Interest is payable only on maturity. The following events constitute an event of default under the OSR Holdings Promissory Note: (i) a failure to pay the outstanding balance due within five (5) business days of the Maturity Date and (ii) the commencement of a voluntary or involuntary bankruptcy action. The funds are to be used by OSR Holdings for working capital and other expenses of OSR Holdings.

The OSR Holdings Promissory Note is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The disclosures set forth in this Item 1.01 are intended to be summaries only and are qualified in their entirety by reference to the OSR Holdings Promissory Note.

Additional Information and Where to Find It

The Company has filed with the Securities and Exchange Commission (“SEC”) a Registration Statement on Form S-4 (as may be amended, the “Registration Statement”), which includes a preliminary proxy statement of the Company and a prospectus in connection with the proposed Business Combination pursuant to an Amended and Restated Business Combination Agreement by and among the Company, OSR Holdings, each stockholder of OSR Holdings that executes a Participating Stockholder Joinder thereto, and each stockholder of OSR Holdings that executes a Non-Participating Stockholder Joinder thereto. The definitive proxy statement and other relevant documents will be mailed to stockholders of the Company as of a record date to be established for voting on the Company’s proposed Business Combination. STOCKHOLDERS OF THE COMPANY AND OTHER INTERESTED PARTIES ARE URGED TO READ, WHEN AVAILABLE, THE PRELIMINARY PROXY STATEMENT, AND AMENDMENTS THERETO, AND THE DEFINITIVE PROXY STATEMENT IN CONNECTION WITH THE COMPANY’S SOLICITATION OF PROXIES FOR THE SPECIAL MEETING OF ITS STOCKHOLDERS TO BE HELD TO APPROVE THE BUSINESS COMBINATION BECAUSE THESE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, OSR HOLDINGS AND THE BUSINESS COMBINATION. Stockholders will also be able to obtain copies of the Registration Statement and the proxy statement/prospectus, without charge, once available, on the SEC’s website at www.sec.gov, or by directing a request to the Company by contacting Jun Chul Whang, c/o Bellevue Life Sciences Acquisition Corp., 10900 NE 4th Street, Suite 2300, Bellevue, WA 98004 or by email at group@bellevuecm.com.

Participants in the Solicitation

The Company, OSR Holdings and their respective directors, executive officers and other members of their management and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of the Company’s stockholders in connection with the proposed business combination. Investors and security holders may obtain more detailed information regarding the names, affiliations and interests of the Company’s directors and officers in the Registration Statement and the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which was filed with the SEC on April 17, 2024, and its registration statement on Form S-1 for its initial public offering. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to the Company’s stockholders in connection with the proposed business combination is set forth in the Registration Statement. Information concerning the interests of the Company’s and OSR Holdings’ equity holders and participants in the solicitation, which may, in some cases, be different than those of the Company’s and the OSR Holdings’ equity holders generally, are set forth in the Registration Statement.

Forward-Looking Statements

This Current Report on Form 8-K includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of the businesses of BLAC and the Company may differ from their actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “proposed,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the satisfaction of the closing conditions to the proposed business combination, the timing of the completion of the proposed business combination and the future performance of the Company, including the anticipated impact of the proposed business combination on this performance. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of the Company and OSR Holdings and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive agreement with respect to the proposed business combination, (2) the outcome of any legal proceedings that may be instituted against the parties in connection with the proposed

business combination; (3) the inability to complete the proposed business combination, including due to failure to obtain approval of the stockholders of the Company or the failure of any other conditions to closing; (4) the impact of the COVID-19 pandemic (or any other global health disruption) on (x) the parties' ability to consummate the proposed business combination and (y) the business of OSR Holdings and the surviving company; (5) the receipt of an unsolicited offer from another party for an alternative business transaction that could interfere with the proposed business combination; (6) the inability to obtain or maintain the listing of the surviving company's common stock on Nasdaq or any other national stock exchange following the proposed business combination; (7) the risk that the consummation of the proposed business combination disrupts the current plans and operations of OSR Holdings; (8) the ability to recognize the anticipated benefits of the proposed business combination, which may be affected by, among other things, competition, the ability of the surviving company to continue to raise additional capital to finance operations and to retain its key employees; (9) costs related to the proposed business combination; (10) changes in applicable laws or regulations; (11) the demand for the Company's and the surviving company's technologies, products or product candidates together with the possibility that the Company and/or the surviving company may be adversely affected by other economic, business, and/or competitive factors; (12) risks and uncertainties related to OSR Holdings' business; and (13) other risks and uncertainties included in (x) the "Risk Factors" sections of the Registration Statement, the most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC by the Company and (y) other documents filed or to be filed with the SEC by the Company. The foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company and OSR Holdings do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions, or circumstances on which any such statement is based.

No Offer or Solicitation

This Current Report on Form 8-K shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This Current Report on Form 8-K shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	
------------------------	--

10.1	Promissory Note, dated October 25, 2024, issued by OSR Holdings Co., Ltd. to Bellevue Life Sciences Acquisition Corp.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 28, 2024

BELLEVUE LIFE SCIENCES ACQUISITION CORP.

By: /s/ Kuk Hyoun Hwang

Name: Kuk Hyoun Hwang

Title: Chief Executive Officer

PROMISSORY NOTE

Principal Amount: \$300,000

Dated October 25, 2024

OSR Holdings Co., Ltd., a corporation organized under the laws of the Republic of Korea (the “**Maker**”), promises to pay to the order of Bellevue Life Sciences Acquisition Corp., a Delaware corporation (the “**Payee**”), or its registered assigns or successors in interest, the principal sum of three hundred thousand dollars (\$300,000) in lawful money of the United States of America, on the terms and conditions described below. All payments on this note (“**Note**”) shall be made by check or wire transfer of immediately available funds or as otherwise determined by the Maker to such account as the Payee may from time to time designate by written notice in accordance with the provisions of this Note.

1. Principal. The principal balance of this Note shall be payable by the Maker on the one-year anniversary of the date first set forth above (the “**Maturity Date**”). The principal balance and unpaid accrued interest may be prepaid at any time. Under no circumstances shall any individual, including but not limited to any manager, member, officer, director, employee or stockholder of the Maker, be obligated personally for any obligations or liabilities of the Maker hereunder.

2. Interest. Interest on the unpaid principal balance of this Note shall accrue at the rate of three and ninety-six hundredths’ percent (3.96%) per annum and shall be compound semi-annually. Accrued interest shall be payable on the Maturity Date.

3. Representations and Warranties of Maker. Maker represents and warrants to Payee on the date hereof as follows:

(a) Existence. Maker is a corporation duly incorporated, validly existing and in good standing under the laws of the Republic of Korea.

(b) Power and Authority. Maker has the power and authority, and the legal right, to execute and deliver this Note and to perform its obligations hereunder.

(c) Authorization; Execution and Delivery. The execution and delivery of this Note by Maker and the performance of its obligations hereunder have been duly authorized by all necessary corporate action in accordance with all applicable laws. The Maker has duly executed and delivered this Note.

(d) No Approvals. No consent or authorization of, filing with, notice to or other act by, or in respect of, any governmental authority is required in order for Maker to execute, deliver, or perform any of its obligations under this Note.

(e) No Violations. The execution and delivery of this Note and the consummation by the Maker of the transactions contemplated hereby do not and will not (a) violate any provision of Maker’ s organizational documents; (b) violate any law applicable to the Maker or by which any of its properties or assets may be bound; or (c) constitute a default under any material agreement or contract by which Maker may be bound.

(f) Enforceability. The Note is a valid, legal and binding obligation of Maker, enforceable against Maker in accordance with its terms except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors’ rights generally and by general equitable principles (whether enforcement is sought by proceedings in equity or at law).

4. Events of Default. Each of the following shall constitute an event of default (“**Event of Default**”):

(a) Failure to Make Required Payments. Failure by Maker to pay the outstanding balance due pursuant to this Note within five (5) business days of the Maturity Date.

(b) Voluntary Bankruptcy, Etc. The commencement by Maker of a voluntary case under any applicable bankruptcy, insolvency, reorganization, rehabilitation or other similar law, or the consent by it to the appointment of or taking possession by a receiver, liquidator, assignee, trustee, custodian, sequestrator (or other similar official) of Maker or for any substantial part of its property, or the making by it of any assignment for the benefit of creditors, or the failure of Maker generally to pay its debts as such debts become due, or the taking of corporate action by Maker in furtherance of any of the foregoing.

(c) Involuntary Bankruptcy, Etc. The entry of a decree or order for relief by a court having jurisdiction in the premises in respect of Maker in an involuntary case under any applicable bankruptcy, insolvency or other similar law, or appointing a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar official) of Maker or for any substantial part of its property, or ordering the winding-up or liquidation of its affairs, and the continuance of any such decree or order unstayed and in effect for a period of 60 consecutive days.

5. Remedies.

(a) Upon the occurrence of an Event of Default specified in Section 4(a) hereof, Payee may, by written notice to Maker, declare this Note to be due immediately and payable, whereupon the outstanding balance of this Note, and all other amounts payable hereunder, shall become immediately due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived, anything contained herein or in the documents evidencing the same to the contrary notwithstanding.

(b) Upon the occurrence of an Event of Default specified in Sections 4(b) and 4(c), the unpaid principal balance of this Note, and all other sums payable with regard to this Note, shall automatically and immediately become due and payable, in all cases without any action on the part of Payee.

6. Waivers. Maker and all endorsers and guarantors of, and sureties for, this Note waive presentment for payment, demand, notice of dishonor and notice of protest with regard to the Note, all errors, defects and imperfections in any proceedings instituted by Payee under the terms of this Note, and all benefits that might accrue to Maker by virtue of any present or future laws exempting any property, real or personal, or any part of the proceeds arising from any sale of any such property, from attachment, levy or sale under execution, or providing for any stay of execution, exemption from civil process, or extension of time for payment; and Maker agrees that any real estate that may be levied upon pursuant to a judgment obtained by virtue hereof, or any writ of execution issued hereon, may be sold upon any such writ in whole or in part in any order desired by Payee.

7. Unconditional Liability. Maker hereby waives all notices in connection with the delivery, acceptance, performance, default, or enforcement of the payment of this Note, and agrees that its liability shall be unconditional, without regard to the liability of any other party, and shall not be affected in any manner by any indulgence, extension of time, renewal, waiver or modification granted or consented to by Payee, and consents to any and all extensions of time, renewals, waivers, or modifications that may be granted by Payee with respect to the payment or other provisions of this Note, and agrees that additional makers, endorsers, guarantors, or sureties may become parties hereto without notice to Maker or affecting Maker’s liability hereunder.

8. Notices. All notices, statements or other documents which are required or contemplated by this Agreement shall be made in writing and delivered (i) personally or sent by first class registered or certified mail, or overnight courier service, to the address most recently provided to such party or such other address as may be designated in writing by such party, (ii) by facsimile to the number most recently provided to such party or such other fax number as may be designated in writing by such party or (iii) by electronic mail, to the electronic mail address most recently provided to such party or such other electronic mail address as may be designated in writing by such party. Any notice or other communication so transmitted shall be deemed to have been given on the day of delivery, if delivered personally, on the business day following receipt of written confirmation, if sent by facsimile or electronic transmission, one (1) business day after delivery to an overnight courier service or five (5) days after mailing if sent by mail.

9. Construction. THIS NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF NEW YORK, WITHOUT REGARD TO CONFLICT OF LAW PROVISIONS THEREOF.

10. Severability. Any provision contained in this Note which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

11. Amendment; Waiver. Any amendment hereto or waiver of any provision hereof may be made with, and only with, the written consent of the Maker and the Payee.

12. Assignment. No assignment or transfer of this Note or any rights or obligations hereunder may be made by any party hereto (by operation of law or otherwise) without the prior written consent of the other party hereto and any attempted assignment without the required consent shall be void.

[Signature Page Follows]

IN WITNESS WHEREOF, Maker, intending to be legally bound hereby, has caused this Note to be duly executed by the undersigned as of the day and year first above written.

OSR HOLDINGS CO., LTD.

By: /s/ Sang Hoon Kim
Name: Sang Hoon Kim
Title: Chief Executive Officer
Email: [**]

Payee hereby acknowledges and agrees to the foregoing as of the date first written above.

ACKNOWLEDGED AND ACCEPTED

BELLEVUE LIFE SCIENCES ACQUISITION CORP.

By: /s/ Kuk Hyoun Hwang
Name: Kuk Hyoun Hwang
Title: Chief Executive Officer
Email: [**]

**Document and Entity
Information**

Oct. 25, 2024

Document And Entity Information [Line Items]

<u>Amendment Flag</u>	false
<u>Entity Central Index Key</u>	0001840425
<u>Document Type</u>	8-K
<u>Document Period End Date</u>	Oct. 25, 2024
<u>Entity Registrant Name</u>	BELLEVUE LIFE SCIENCES ACQUISITION CORP.
<u>Entity Incorporation State Country Code</u>	DE
<u>Entity File Number</u>	001-41390
<u>Entity Tax Identification Number</u>	84-5052822
<u>Entity Address, Address Line One</u>	10900 NE 4th Street
<u>Entity Address, Address Line Two</u>	Suite 2300
<u>Entity Address, City or Town</u>	Bellevue
<u>Entity Address, State or Province</u>	WA
<u>Entity Address, Postal Zip Code</u>	98004
<u>City Area Code</u>	(425)
<u>Local Phone Number</u>	635-7700
<u>Written Communications</u>	true
<u>Soliciting Material</u>	false
<u>Pre Commencement Tender Offer</u>	false
<u>Pre Commencement Issuer Tender Offer</u>	false
<u>Entity Emerging Growth Company</u>	true
<u>Entity Ex Transition Period</u>	false

Units Each Consisting Of One Share Of Common Stock
One Redeemable Warrant And One Right 2 [Member]

Document And Entity Information [Line Items]

<u>Security 12b Title</u>	Units, each consisting of one share of common stock, one redeemable warrant and one right
<u>Trading Symbol</u>	BLACU
<u>Security Exchange Name</u>	NASDAQ

Common Stock [Member]

Document And Entity Information [Line Items]

<u>Security 12b Title</u>	Common stock, par value \$0.0001 per share
<u>Trading Symbol</u>	BLAC
<u>Security Exchange Name</u>	NASDAQ

Redeemable Warrants Exercisable For Shares Of Common
Stock At An Exercise Price Of 11.50 Per Share 1 [Member]

Document And Entity Information [Line Items]

<u>Security 12b Title</u>	Redeemable warrants, exercisable for shares of common stock at an exercise price of \$11.50 per share
<u>Trading Symbol</u>	BLACW

Security Exchange Name

NASDAQ

Right To Receive Onetenth 110 Of One Share Of Common
Stock [Member]

Document And Entity Information [Line Items]

Security 12b Title

Right to receive one-tenth (1/10) of one share of
common stock

Trading Symbol

BLACR

Security Exchange Name

NASDAQ

```

{
  "version": "2.2",
  "instance": {
    "id": "889585d8k.htm": {
      "nsPrefix": "blacu",
      "nsURI": "http://BellevueLifeSciencesAcquisitionCorp.com/20241025",
      "dts": {
        "schemas": {
          "local": {
            "blacu-20241025.xsd"
          },
          "remote": {
            "http://www.abri.org/2003/abri-instance-2003-12-31.xsd",
            "http://www.abri.org/2003/abri-linkbase-2003-12-31.xsd",
            "http://www.abri.org/2003/xl-2003-12-31.xsd",
            "http://www.abri.org/2003/xlink-2003-12-31.xsd",
            "http://www.abri.org/2005/abridt-2005.xsd",
            "http://www.abri.org/2006/ref-2006-02-27.xsd",
            "http://www.abri.org/dtr/type/nonNumeric-2009-12-16.xsd",
            "http://www.abri.org/dtr/type/numeric-2009-12-16.xsd",
            "https://www.abri.org/2020/accessible-nomenclatures-2.0.xsd",
            "https://www.abri.org/dtr/type/2020-01-21/types.xsd",
            "https://www.abri.org/dtr/type/2022-03-31/types.xsd",
            "https://abri.fash.org/act/2023/atta/act-2023.xsd",
            "https://abri.fash.org/act/2023/atta/act-roles-2023.xsd",
            "https://abri.fash.org/act/2023/atta/act-types-2023.xsd",
            "https://abri.fash.org/us-gaap/2023/atta/us-gaap-2023.xsd",
            "https://abri.fash.org/us-gaap/2023/atta/us-roles-2023.xsd",
            "https://abri.fash.org/us-gaap/2023/atta/us-types-2023.xsd",
            "https://abri.sec.gov/country/2023/country-2023.xsd",
            "https://abri.sec.gov/del/2023/del-2023.xsd",
            "https://abri.sec.gov/naics/2023/naics-2023.xsd"
          }
        },
        "definitionLink": {
          "local": {
            "blacu-20241025_def.xml"
          },
          "labelLink": {
            "local": {
              "blacu-20241025_lab.xml"
            }
          },
          "presentationLink": {
            "local": {
              "blacu-20241025_pre.xml"
            }
          },
          "inline": {
            "local": {
              "889585d8k.htm"
            }
          }
        },
        "keyStandard": 24,
        "keyCustom": 0,
        "axisStandard": 1,
        "axisCustom": 0,
        "memberStandard": 1,
        "memberCustom": 3,
        "hidden": {
          "total": 2,
          "http://abri.sec.gov/del/2023": 2
        },
        "contextCount": 5,
        "entityCount": 1,
        "segmentCount": 4,
        "elementCount": 33,
        "unitCount": 0,
        "baseTaxonomies": {
          "http://abri.sec.gov/del/2023": 33
        },
        "report": {
          "xsi": {
            "role": "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation",
            "longName": "10000 - Document - Document and Entity Information",
            "shortName": "Document and Entity Information",
            "isDefault": "true",
            "groupType": "Document",
            "subGroupType": "",
            "document": "Cover",
            "order": "1",
            "firstAnchor": {
              "contactRef": "duration_2024-10-25_to_2024-10-25",
              "name": "del:DocumentType",
              "unitRef": null,
              "xsiNil": "false",
              "lang": "en-US",
              "decimal": null,
              "ancestors": [
                "sgap",
                "p",
                "div",
                "div",
                "body",
                "html"
              ]
            },
            "reportCount": 1,
            "baseRef": "889585d8k.htm",
            "first": true,
            "unique": true
          },
          "uniqueAnchor": {
            "contactRef": "duration_2024-10-25_to_2024-10-25",
            "name": "del:DocumentType",
            "unitRef": null,
            "xsiNil": "false",
            "lang": "en-US",
            "decimal": null,
            "ancestors": [
              "sgap",
              "p",
              "div",
              "div",
              "body",
              "html"
            ]
          },
          "reportCount": 1,
          "baseRef": "889585d8k.htm",
          "first": true,
          "unique": true
        }
      },
      "tag": {
        "del_AmendmentFlag": {
          "abbrType": "booleanItemType",
          "nsURI": "http://abri.sec.gov/del/2023",
          "localName": "AmendmentFlag",
          "presentation": {
            "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
          },
          "lang": {
            "en-us": {
              "role": {
                "label": "Amendment Flag",
                "targetLabel": "Amendment Flag",
                "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
              }
            }
          },
          "auth_ref": []
        },
        "del_CityAreaCode": {
          "abbrType": "normalizedStringItemType",
          "nsURI": "http://abri.sec.gov/del/2023",
          "localName": "CityAreaCode",
          "presentation": {
            "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
          },
          "lang": {
            "en-us": {
              "role": {
                "label": "City Area Code",
                "targetLabel": "City Area Code",
                "documentation": "Area code of city"
              }
            }
          },
          "auth_ref": []
        },
        "us-gaap_ClassOfStockDomain": {
          "abbrType": "domainItemType",
          "nsURI": "http://fash.org/us-gaap/2023",
          "localName": "ClassOfStockDomain",
          "presentation": {
            "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
          },
          "lang": {
            "en-us": {
              "role": {
                "label": "Class of Stock [Domain]",
                "targetLabel": "Class of Stock [Domain]"
              }
            }
          },
          "auth_ref": []
        },
        "us-gaap_CommonStockMember": {
          "abbrType": "domainItemType",
          "nsURI": "http://fash.org/us-gaap/2023",
          "localName": "CommonStockMember",
          "presentation": {
            "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
          },
          "lang": {
            "en-us": {
              "role": {
                "label": "Common Stock [Member]",
                "targetLabel": "Common Stock [Member]"
              }
            }
          },
          "auth_ref": []
        },
        "del_CoverAbstract": {
          "abbrType": "stringItemType",
          "nsURI": "http://abri.sec.gov/del/2023",
          "localName": "CoverAbstract",
          "lang": {
            "en-us": {
              "role": {

```

```

        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
    }
},
"auth_ref": []
},
"del DocumentAndEntityInformationLineItems": {
    "shrType": "RatingItemTypes",
    "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20241025",
    "localname": "DocumentAndEntityInformationLineItems",
    "presentation": {
        "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
        "en-us": {
            "role": {
                "label": "Document And Entity Information [line items]",
                "terseLabel": "Document And Entity Information [line items]"
            }
        }
    },
    "auth_ref": []
},
"del DocumentAndEntityInformationTable": {
    "shrType": "RatingItemTypes",
    "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20241025",
    "localname": "DocumentAndEntityInformationTable",
    "presentation": {
        "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
        "en-us": {
            "role": {
                "label": "Document And Entity Information [Table]",
                "terseLabel": "Document And Entity Information [Table]"
            }
        }
    },
    "auth_ref": []
},
"del DocumentPeriodEndDate": {
    "shrType": "NarrativeTypes",
    "nsuri": "http://xbrl.sec.gov/dsl/2023",
    "localname": "DocumentPeriodEndDate",
    "presentation": {
        "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
        "en-us": {
            "role": {
                "label": "Document Period End Date",
                "terseLabel": "Document Period End Date",
                "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; For the EDGAR submission types of Form 10-K: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
            }
        }
    },
    "auth_ref": []
},
"del DocumentType": {
    "shrType": "SubmissionTypeItemTypes",
    "nsuri": "http://xbrl.sec.gov/dsl/2023",
    "localname": "DocumentType",
    "presentation": {
        "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
        "en-us": {
            "role": {
                "label": "Document Type",
                "terseLabel": "Document Type",
                "documentation": "The type of document being provided (such as 10-K, 10-Q, 485POB, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
            }
        }
    },
    "auth_ref": []
},
"del EntityAddressAddressLine1": {
    "shrType": "NormalizedStringItemTypes",
    "nsuri": "http://xbrl.sec.gov/dsl/2023",
    "localname": "EntityAddressAddressLine1",
    "presentation": {
        "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
        "en-us": {
            "role": {
                "label": "Entity Address, Address Line One",
                "terseLabel": "Entity Address, Address Line One",
                "documentation": "Address line 1 such as Attn, Building Name, Street Name"
            }
        }
    },
    "auth_ref": []
},
"del EntityAddressAddressLine2": {
    "shrType": "NormalizedStringItemTypes",
    "nsuri": "http://xbrl.sec.gov/dsl/2023",
    "localname": "EntityAddressAddressLine2",
    "presentation": {
        "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
        "en-us": {
            "role": {
                "label": "Entity Address, Address Line Two",
                "terseLabel": "Entity Address, Address Line Two",
                "documentation": "Address line 2 such as Street or Suite number"
            }
        }
    },
    "auth_ref": []
},
"del EntityAddressCityOrTown": {
    "shrType": "NormalizedStringItemTypes",
    "nsuri": "http://xbrl.sec.gov/dsl/2023",
    "localname": "EntityAddressCityOrTown",
    "presentation": {
        "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
        "en-us": {
            "role": {
                "label": "Entity Address, City or Town",
                "terseLabel": "Entity Address, City or Town",
                "documentation": "Name of the City or Town"
            }
        }
    },
    "auth_ref": []
},
"del EntityAddressPostalZipCode": {
    "shrType": "NormalizedStringItemTypes",
    "nsuri": "http://xbrl.sec.gov/dsl/2023",
    "localname": "EntityAddressPostalZipCode",
    "presentation": {
        "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
        "en-us": {
            "role": {
                "label": "Entity Address, Postal Zip Code",
                "terseLabel": "Entity Address, Postal Zip Code",
                "documentation": "Code For the postal or zip code"
            }
        }
    },
    "auth_ref": []
},
"del EntityAddressStateOrProvince": {
    "shrType": "StateOrProvincialItemTypes",
    "nsuri": "http://xbrl.sec.gov/dsl/2023",
    "localname": "EntityAddressStateOrProvince",
    "presentation": {
        "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
        "en-us": {
            "role": {
                "label": "Entity Address, State or Province",
                "terseLabel": "Entity Address, State or Province",
                "documentation": "Name of the state or province."
            }
        }
    },
    "auth_ref": []
},
"del EntityCentralIndexKey": {
    "shrType": "CentralIndexKeyItemTypes",
    "nsuri": "http://xbrl.sec.gov/dsl/2023",
    "localname": "EntityCentralIndexKey",
    "presentation": {
        "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
        "en-us": {
            "role": {
                "label": "Entity Central Index Key",
                "terseLabel": "Entity Central Index Key",
                "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
            }
        }
    },
    "auth_ref": [
        "cik"
    ]
},
"del EntityEmergingGrowthCompany": {
    "shrType": "BooleanItemTypes",
    "nsuri": "http://xbrl.sec.gov/dsl/2023",
    "localname": "EntityEmergingGrowthCompany",
    "presentation": {
        "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
        "en-us": {
            "role": {
                "label": "Entity Emerging Growth Company",
                "terseLabel": "Entity Emerging Growth Company",
                "documentation": "Indicate if registrant meets the emerging growth company criteria."
            }
        }
    },
    "auth_ref": []
}

```

```

"p1"
},
{
  "del_EntityExTransitionPeriod": {
    "shortType": "booleanItemType",
    "nsuri": "http://xbrl.sec.gov/del/2023",
    "localname": "EntityExTransitionPeriod",
    "presentation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
      "nsuri": {
        "role": {
          "label": "Entity Ex Transition Period",
          "targetLabel": "Entity Ex Transition Period",
          "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
        }
      }
    },
    "auth_ref": {
      "p3"
    }
  },
  "del_EntityFileNumber": {
    "shortType": "stringItemType",
    "nsuri": "http://xbrl.sec.gov/del/2023",
    "localname": "EntityFileNumber",
    "presentation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
      "nsuri": {
        "role": {
          "label": "Entity File Number",
          "targetLabel": "Entity File Number",
          "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
        }
      }
    },
    "auth_ref": {
    }
  },
  "del_EntityIncorporationStateCountryCode": {
    "shortType": "stringItemType",
    "nsuri": "http://xbrl.sec.gov/del/2023",
    "localname": "EntityIncorporationStateCountryCode",
    "presentation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
      "nsuri": {
        "role": {
          "label": "Entity Incorporation State Country Code",
          "targetLabel": "Entity Incorporation State Country Code",
          "documentation": "Two-character EDGAR code representing the state or country of incorporation."
        }
      }
    },
    "auth_ref": {
    }
  },
  "del_EntityRegistrantName": {
    "shortType": "normalizedStringItemType",
    "nsuri": "http://xbrl.sec.gov/del/2023",
    "localname": "EntityRegistrantName",
    "presentation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
      "nsuri": {
        "role": {
          "label": "Entity Registrant Name",
          "targetLabel": "Entity Registrant Name",
          "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
        }
      }
    },
    "auth_ref": {
      "p1"
    }
  },
  "del_EntityTaxIdentificationNumber": {
    "shortType": "stringItemType",
    "nsuri": "http://xbrl.sec.gov/del/2023",
    "localname": "EntityTaxIdentificationNumber",
    "presentation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
      "nsuri": {
        "role": {
          "label": "Entity Tax Identification Number",
          "targetLabel": "Entity Tax Identification Number",
          "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
        }
      }
    },
    "auth_ref": {
      "p1"
    }
  },
  "del_LocalPhoneNumber": {
    "shortType": "normalizedStringItemType",
    "nsuri": "http://xbrl.sec.gov/del/2023",
    "localname": "LocalPhoneNumber",
    "presentation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
      "nsuri": {
        "role": {
          "label": "Local Phone Number",
          "targetLabel": "Local Phone Number",
          "documentation": "Local phone number for entity."
        }
      }
    },
    "auth_ref": {
    }
  },
  "del_PreCommencementIssuerTenderOffer": {
    "shortType": "booleanItemType",
    "nsuri": "http://xbrl.sec.gov/del/2023",
    "localname": "PreCommencementIssuerTenderOffer",
    "presentation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
      "nsuri": {
        "role": {
          "label": "Pre Commencement Issuer Tender Offer",
          "targetLabel": "Pre Commencement Issuer Tender Offer",
          "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13a-4(c) under the Exchange Act."
        }
      }
    },
    "auth_ref": {
      "p3"
    }
  },
  "del_PreCommencementTenderOffer": {
    "shortType": "booleanItemType",
    "nsuri": "http://xbrl.sec.gov/del/2023",
    "localname": "PreCommencementTenderOffer",
    "presentation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
      "nsuri": {
        "role": {
          "label": "Pre Commencement Tender Offer",
          "targetLabel": "Pre Commencement Tender Offer",
          "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
        }
      }
    },
    "auth_ref": {
      "p4"
    }
  },
  "discu_RedeemableWarrantsExercisableForSharesOfCommonStockAtAnExercisePriceOf11.50PerShare1Member": {
    "shortType": "domainItemType",
    "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20241025",
    "localname": "RedeemableWarrantsExercisableForSharesOfCommonStockAtAnExercisePriceOf11.50PerShare1Member",
    "presentation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
      "nsuri": {
        "role": {
          "label": "Redeemable Warrants Exercisable For Shares Of Common Stock At An Exercise Price Of 11.50 Per Share 1 [Member]",
          "targetLabel": "Redeemable Warrants Exercisable For Shares Of Common Stock At An Exercise Price Of 11.50 Per Share 1 [Member]"
        }
      }
    },
    "auth_ref": {
    }
  },
  "discu_RightToReceiveOneTenth110OfOneShareOfCommonStockMember": {
    "shortType": "domainItemType",
    "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20241025",
    "localname": "RightToReceiveOneTenth110OfOneShareOfCommonStockMember",
    "presentation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
      "nsuri": {
        "role": {
          "label": "Right To Receive OneTenth 110 Of One Share Of Common Stock [Member]",
          "targetLabel": "Right To Receive OneTenth 110 Of One Share Of Common Stock [Member]"
        }
      }
    },
    "auth_ref": {
    }
  },
  "del_Security12bTitle": {
    "shortType": "securityTitleItemType",
    "nsuri": "http://xbrl.sec.gov/del/2023",
    "localname": "Security12bTitle",
    "presentation": {
      "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    },
    "lang": {
      "nsuri": {
        "role": {
          "label": "Security 12b Title",
          "targetLabel": "Security 12b Title",
          "documentation": "Title of a 12(b) registered security."
        }
      }
    }
  }
}

```

```

    },
    "auth_ref": [
        "e0"
    ]
},
"dei_SecurityExchangeName": {
    "xbrlType": "xsd:stringItemType",
    "nsuri": "http://xbrl.sec.gov/dei/2023",
    "localname": "SecurityExchangeName",
    "presentation": [
        "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    ],
    "lang": {
        "en-us": {
            "role": {
                "label": "Security Exchange Name",
                "targetLabel": "Security Exchange Name",
                "documentation": "Name of the Exchange on which a security is registered."
            }
        }
    },
    "auth_ref": [
        "e2"
    ]
},
"dei_SolicitingMaterial": {
    "xbrlType": "booleanItemType",
    "nsuri": "http://xbrl.sec.gov/dei/2023",
    "localname": "SolicitingMaterial",
    "presentation": [
        "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    ],
    "lang": {
        "en-us": {
            "role": {
                "label": "Soliciting Material",
                "targetLabel": "Soliciting Material",
                "documentation": "Boolean flag that is true when the Form S-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 144+12 under the Exchange Act."
            }
        }
    },
    "auth_ref": [
        "e3"
    ]
},
"us-gaap_StatementClassOfStockAxis": {
    "xbrlType": "stringItemType",
    "nsuri": "http://xbrl.sec.gov/us-gaap/2023",
    "localname": "StatementClassOfStockAxis",
    "presentation": [
        "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    ],
    "lang": {
        "en-us": {
            "role": {
                "label": "Class of Stock [Axis]",
                "targetLabel": "Class of Stock [Axis]"
            }
        }
    },
    "auth_ref": []
},
"dei_TradingSymbol": {
    "xbrlType": "stringItemType",
    "nsuri": "http://xbrl.sec.gov/dei/2023",
    "localname": "TradingSymbol",
    "presentation": [
        "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    ],
    "lang": {
        "en-us": {
            "role": {
                "label": "Trading Symbol",
                "targetLabel": "Trading Symbol",
                "documentation": "Trading symbol of an instrument as listed on an exchange."
            }
        }
    },
    "auth_ref": []
},
"disco_UnitsEachConsistingOfOneShareOfCommonStockOneRedeemableWarrantAndOneRight2Member": {
    "xbrlType": "domainItemType",
    "nsuri": "http://BellevueLifeSciencesAcquisitionCorp.com/20241025",
    "localname": "UnitsEachConsistingOfOneShareOfCommonStockOneRedeemableWarrantAndOneRight2Member",
    "presentation": [
        "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    ],
    "lang": {
        "en-us": {
            "role": {
                "label": "Units Each Consisting Of One Share Of Common Stock One Redeemable Warrant And One Right 2 [Member]",
                "targetLabel": "Units Each Consisting Of One Share Of Common Stock One Redeemable Warrant And One Right 2 [Member]"
            }
        }
    },
    "auth_ref": []
},
"dei_WrittenCommunications": {
    "xbrlType": "booleanItemType",
    "nsuri": "http://xbrl.sec.gov/dei/2023",
    "localname": "WrittenCommunications",
    "presentation": [
        "http://BellevueLifeSciencesAcquisitionCorp.com/20241025/taxonomy/role/DocumentDocumentAndEntityInformation"
    ],
    "lang": {
        "en-us": {
            "role": {
                "label": "Written Communications",
                "targetLabel": "Written Communications",
                "documentation": "Boolean flag that is true when the Form S-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
            }
        }
    },
    "auth_ref": [
        "e6"
    ]
}
}
},
"add_ref": {
    "e0": {
        "role": "http://www.xbrl.org/2003/role/presentationRef",
        "publisher": "SEC",
        "name": "Exchange Act",
        "number": "240",
        "section": "12",
        "subsection": "b"
    },
    "e1": {
        "role": "http://www.xbrl.org/2003/role/presentationRef",
        "publisher": "SEC",
        "name": "Exchange Act",
        "number": "240",
        "section": "12",
        "subsection": "b-2"
    },
    "e2": {
        "role": "http://www.xbrl.org/2003/role/presentationRef",
        "publisher": "SEC",
        "name": "Exchange Act",
        "number": "240",
        "section": "12",
        "subsection": "d1-1"
    },
    "e3": {
        "role": "http://www.xbrl.org/2003/role/presentationRef",
        "publisher": "SEC",
        "name": "Exchange Act",
        "number": "240",
        "section": "13a",
        "subsection": "4c"
    },
    "e4": {
        "role": "http://www.xbrl.org/2003/role/presentationRef",
        "publisher": "SEC",
        "name": "Exchange Act",
        "number": "240",
        "section": "14",
        "subsection": "2b"
    },
    "e5": {
        "role": "http://www.xbrl.org/2003/role/presentationRef",
        "publisher": "SEC",
        "name": "Exchange Act",
        "section": "14",
        "number": "240",
        "subsection": "12"
    },
    "e6": {
        "role": "http://www.xbrl.org/2003/role/presentationRef",
        "publisher": "SEC",
        "name": "Securities Act",
        "number": "230",
        "section": "425"
    },
    "e7": {
        "role": "http://www.xbrl.org/2003/role/presentationRef",
        "publisher": "SEC",
        "name": "Securities Act",
        "number": "13a",
        "section": "8",
        "subsection": "2"
    }
}
}
}

```